|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administered_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:2018
gptkb:FDA
|
|
gptkbp:available_in
|
multiple countries
|
|
gptkbp:brand
|
gptkb:Aimovig
|
|
gptkbp:clinical_trial
|
improved quality of life
Phase III
reduced monthly migraine days
|
|
gptkbp:clinical_use
|
chronic migraine
episodic migraine
|
|
gptkbp:contraindication
|
hypersensitivity to the drug
|
|
gptkbp:developed_by
|
gptkb:Amgen
|
|
gptkbp:dosage_form
|
pre-filled syringe
once monthly
|
|
gptkbp:formulation
|
solution for injection
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
erenumab
|
|
gptkbp:indication
|
preventive treatment of migraine
|
|
gptkbp:ingredients
|
gptkb:erenumab-aooe
|
|
gptkbp:invention
|
2028
|
|
gptkbp:manufacturer
|
gptkb:Amgen_Inc.
|
|
gptkbp:marketed_as
|
gptkb:Aimovig
|
|
gptkbp:mechanism_of_action
|
CGRP receptor antagonist
|
|
gptkbp:pharmacokinetics
|
long half-life
CGRP inhibition
|
|
gptkbp:research_areas
|
neurology
pain management
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
constipation
injection site reactions
muscle spasms
|
|
gptkbp:targets
|
CGRP receptor
|
|
gptkbp:used_for
|
migraine prevention
|
|
gptkbp:bfsParent
|
gptkb:Aimovig
|
|
gptkbp:bfsLayer
|
5
|